logo
100 years ago, scientists thought we'd be eating food made from air

100 years ago, scientists thought we'd be eating food made from air

Yahoo4 days ago
In the early 1920s, on the left bank of the Seine just outside Paris, a small laboratory garden bloomed on a plot of land sandwiched between the soaring Paris Observatory and the sprawling grounds of Chalais Park. Unlike a typical garden filled with well-groomed plants and the smell of fresh-turned soil, this garden had an industrial feel. Dubbed 'the Garden of Wonders' by a contemporary journalist, the plot was lined with elevated white boxes fed with water from large glass canisters. Nearby greenhouses included equally unusual accessories. But it's what happened inside the low-slung laboratory buildings that made this garden so wondrous.
In August 1925, Popular Science contributing writer Norman C. McCloud described how Daniel Berthelot—a decorated chemist and physicist from France—was conducting revolutionary 'factory-made vegetable' experiments in his Garden of Wonders. Berthelot, son of Marcellin Berthelot, a renowned 19th century chemist and French diplomat, was using the garden to expand upon his father's groundbreaking work. Starting in 1851, the elder Berthelot began creating synthetic organic compounds, such as fats and sugars (he coined the name 'triglyceride'), from inorganic compounds like hydrogen, carbon, oxygen, and nitrogen. It was a revolutionary first step toward artificial food.
'[The younger] Berthelot already has produced foodstuffs artificially by subjecting various gases to the influence of ultra-violet light,' wrote McCloud. 'These experiments,' he added, quoting Berthelot, 'show that by means of light, vegetable foods can be manufactured from air gases.' But Berthelot's experiment didn't exactly catch on. A century later, most food is still grown the traditional way—by plants—but the idea of manufacturing food in controlled, factory environments has been gaining ground. In fact, Berthelot's revolutionary idea may finally be bearing fruit—just not in the way he imagined.
A revolution in food chemistry
Berthelot never fully accomplished his goal of trying to artificially reproduce what plants do naturally. Nonetheless, his experiments, as sensational as they might seem today, would have been considered quite plausible in 1925. That's because his father's discoveries had unleashed a revolution in chemistry and a tidal wave of optimism about the future of food. By the 1930s, chemists had begun synthesizing everything from basic nutrients, like vitamins, to medicines, like aspirin (acetylsalicylic acid), to food additives, such as artificial thickeners, emulsifiers, colors, and flavors.
In an interview for McClure's magazine in 1894 dubbed 'Foods in the Year 2000,' Berthelot's father boldly predicted that all foods would be artificial by the year 2000. 'The epicure of the future is to dine upon artificial meat, artificial flour, and artificial vegetables,' wrote Henry Dam for McClure's, articulating Marcellin Berthelot's vision. 'Wheat fields and corn fields are to disappear from the face of the earth. Herds of cattle, flocks of sheep, and droves of swine will cease to be bred because beef and mutton and pork will be manufactured direct[ly] from their elements.'
Welcome to the Garden of Wonders
Such was the vision that the younger Berthelot was pursuing in his Garden of Wonders. His goal, he told McCloud, was to produce 'sugar and starch from the elements without the intervention of living organisms.' To achieve this, Berthelot envisioned a factory with 'glass tanks of great capacity.' Gases would be pumped into the tanks, and 'suspended from the ceiling [would] be lamps producing the rays of ultra-violet light.' Berthelot imagined that when the chemical elements combined 'through the glass walls of the tank we shall see something in the nature of a gentle snowfall that will accumulate on the floor of the tanks…our finished product—vegetable starches and vegetable sugars created in a faithful reproduction of the works of nature.'
By 1925, he had succeeded in using light and gas (carbon, hydrogen, oxygen, and nitrogen) to create the basic compound formamide, which is used to produce sulfa drugs (a kind of synthetic antibiotic) and other medicines as well as industrial products. But his progress toward reproducing photosynthesis ended there. Berthelot died just two years after McCloud's story ran in Popular Science, in 1927, without ever realizing his dream.
Despite the bold predictions of the time, producing food from only air and light was wildly aspirational in 1925, if for no other reason than photosynthesis was poorly understood. The term had only been coined a few decades earlier when Charles Barnes, an influential American botanist, lobbied for a more precise description of a plant's internal mechanisms than the generic 'assimilation' then in favor. Chlorophyll had been discovered in the prior century, but what happened at a cellular level in plants remained largely theoretical until the 1950s. Although Berthelot may have been onto something with his experiments, adding to the momentum that became the artificial food industry, he was a long way from replicating what comes naturally to plants. We still are, but recent discoveries may have enabled a workaround—depending on your definition of 'food.'
A modern answer to Berthelot's innovative garden
From vertical indoor farms to hydroponics to genetically modified crops, since the 1960s commercial agriculture has been focused on coaxing more yield from fewer resources, including land, water, and nutrients. The drive began when Nobel Peace Prize winner Norman Borlaug, an American biologist, helped spark the Green Revolution by selectively breeding a grain-packed, dwarf variety of wheat. The theoretical limit of that revolutionary goal would liberate food production from traditional agriculture altogether, eliminating all resources except air and light—Berthelot's original vision.
In the last century, we've inched toward creating food from nothing, making progress by teasing apart the incredibly complex biochemical pathways associated with plant physiology. But if we've learned anything since Berthelot's experiments, it's that photosynthesis—what plants are naturally programmed to do—can't be easily replicated industrially. But that hasn't stopped a handful of companies from trying.
In April 2024, Solar Foods opened a factory in Vantaa, Finland—a sleek facility where workers monitor large tanks filled with atmospheric gases. Inside the tanks, water transforms into a protein-rich slurry. Dehydrated, the slurry becomes a golden powder packed with protein and other nutrients, ready to be turned into pasta, ice cream, and protein bars. The powdery substance, Solein, resembles Berthelot's vision, as does the factory, which uses atmospheric gases to enable 'food production anywhere in the world,' according to a 2025 company press release, 'as production is not dependent on weather, climate conditions, or land use.' But the similarities with Berthelot's vision end there. Solar Foods may not require land or plants to produce food, but their technology derives from a living organism. Using a form of fermentation, it relies on a microbe to digest air and water to produce protein.
Related Archival Stories
100 years ago, scientists predicted we'd live to 1,000 years old
100 years ago, the battle for television raged
A century ago, suspended monorails were serious mass-transit contenders
100 years of deep-sea filmmaking and ocean exploration
100 years of aliens: From Mars beavers to little gray men
The U.S.-based company Kiverdi uses a similar microbial fermentation process, first devised by NASA as far back as the 1960s for deep space travel, to convert carbon dioxide into protein. Austria-based Arkeon Technologies has developed its own microbial fermentation process to also produce food from carbon dioxide without the need for land or other nutrients. Microbial fermentation may represent a promising new chapter in synthetic foods, but don't expect tomatoes or corn to materialize from thin air anytime soon—it's not artificial photosynthesis.
While Berthelot's understanding of photosynthesis was primitive a century ago, he was ahead of his time in many ways, and his vision was remarkably prescient. Although we still haven't figured out how to replicate photosynthesis chemically—literally growing fruits and vegetables as plants do from air and light—it's worth acknowledging the strides we've made in just the last decade: Companies like Arkeon Technologies and Kiverdi may help remove excess carbon dioxide from the atmosphere while offering solutions to future food shortages. Or they may not. Only the next century will tell.
Solve the daily Crossword
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Type II Vasculitis Signals Poor Prognosis in Sjögren Disease
Type II Vasculitis Signals Poor Prognosis in Sjögren Disease

Medscape

time4 hours ago

  • Medscape

Type II Vasculitis Signals Poor Prognosis in Sjögren Disease

TOPLINE: Among patients with primary Sjögren disease, type II cryoglobulinemic vasculitis is linked to an increased risk for lymphoma and mortality, a French study showed. METHODOLOGY: Researchers conducted a retrospective multicenter cohort study of 54 patients with primary Sjögren disease and cutaneous vasculitis (CV) from three pathology departments in Paris and a national case call in France (median age, 42 years; 91% women). Patients were diagnosed with CV between 2011 and 2021; 29 (57%) had cryoglobulinemic vasculitis and 15 (28%) had hypergammaglobulinemic vasculitis; 24 of the 29 cryoglobulinemic cases were type II. Data were analyzed between March 2023 and March 2025. Patients were matched 1:2 to 108 controls with Sjögren disease but without CV from the French ASSESS cohort. Primary outcomes of the study were the occurrence of lymphoma diagnosis and mortality risk. TAKEAWAY: Patients with Sjögren disease and CV showed a higher lymphoma incidence than those without CV (13% vs 4%; P = .04). Patients with type II cryoglobulinemic vasculitis had a significantly higher incidence of lymphoma (21% vs 0%; P = .02) and increased mortality (29% vs 0; P = .02) than those with other types of small-vessel vasculitis. The risk for death or non-Hodgkin lymphoma was increased by nearly sevenfold risk in patients with type II cryoglobulinemic vasculitis (hazard ratio [HR], 6.8; P = .005) compared with other CV types. Patients with type II cryoglobulinemic vasculitis were more likely to have subacute cutaneous lupus (21% vs 0%; P = .02), kidney involvement (29% vs 4%; P = .02) and peripheral nervous system involvement (63% vs 12%; P < .001) than those with other CV types. Among 24 patients with type II cryoglobulinemic vasculitis, 12 received rituximab-based first-line treatment; non-Hodgkin lymphoma developed in 8% of patients in the rituximab group and in 25% of those who received other treatments, whereas mortality rates were 33% and 25%, respectively. IN PRACTICE: 'In this cohort study, among patients with CV-complicated Sjögren disease, only type II cryoglobulinemic vasculitis was associated with severe visceral involvement, higher risk of non-Hodgkin lymphoma, and mortality,' the study authors wrote. These findings, they added, highlighted the need for 'specific monitoring for these patients.' SOURCE: The study was led by Paul Breillat, MD, INSERM, Paris Centre de Recherche Cardiovasculaire, Paris, France, and was published online on August 6 in JAMA Dermatology. LIMITATIONS: The retrospective design and potential missing data could affect the interpretation of results. Additionally, half of the patients were diagnosed with CV on the basis of clinical criteria. DISCLOSURES: The ASSESS cohort was set up with a grant from the French Ministry of Health. One author reported receiving personal fees from Bristol Myers Squibb, GSK, Novartis, and Otsuka; another author reported receiving grants from AstraZeneca, Bristol Myers Squibb, and GSK. No other disclosures were reported. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

MS Meds Significantly Underprescribed in Women
MS Meds Significantly Underprescribed in Women

Medscape

time6 hours ago

  • Medscape

MS Meds Significantly Underprescribed in Women

Women with multiple sclerosis (MS) are significantly less likely than men to be treated with disease-modifying therapies (DMTs) and highly effective DMTs (HE-DMTs), a new study showed. At comparable levels of disease severity, women had 8% lower odds of receiving any DMT and 20% lower odds of receiving HE-DMT. While pregnancy may partially explain undertreatment in women, this doesn't fully account for the disparity between the sexes. 'When used early, MS drugs can delay the burden of the disease, so women who are not treated could have worse outcomes in the long term and an increased risk of long-term disability. This loss of chance is not acceptable anymore as there are drugs that are compatible with pregnancy or can continue to fight the disease long after people stop them when they are trying to conceive,' study investigator Sandra Vukusic, MD, PhD, University of Lyon in Lyon, France, said in a news release. The study was published online on July 30 in Neurology . Most Patients With MS Are Women The researchers hypothesized that DMTs may be underprescribed in women, particularly during childbearing years, due to potential clinician bias and previously unclear data on the safety of DMTs before, during, and after pregnancy. Although women make up roughly 75% of patients with MS, a study published last year showed women are more likely to be taken off DMTs and less likely to have treatment escalated than men. For the study, the researchers reviewed data of 22,657 patients with relapsing-remitting MS between 1997 and 2022 from the Observatoire Français de la Sclerose en Plaques (74.4% women; mean age at onset, 29 years). The primary outcome was the annual likelihood of each sex prescribed a DMT while accounting for disease severity and periods of pregnancy and postpartum. The second outcome was the annual probability of patients receiving an HE-DMT or a specific DMT, and how this was influenced by sex, accounting for covariates such as time, age, and disease duration. To evaluate the potential impact of pregnancy on prescribing patterns, the researchers analyzed treatment rates in relation to time to childbirth; 36.3% of patients had at least one pregnancy. Data were analyzed using longitudinal logistic modeling with generalized estimating equations and an inverse probability of censoring weighting. Disturbing Disparities Before adjusting for variables, investigators found no significant difference in DMT use between men and women. After adjusting for periods of pregnancy, postpartum, and disease severity, women were significantly less likely than men to receive a DMT (odds ratio [OR], 0.92; 95% CI, 0.87-0.97) and were even less likely to receive an HE-DMT (OR, 0.80; 95% CI, 0.74-0.86). 'Disturbingly, these disparities appeared as early as 1-2 years after disease onset and persisted at least over the first decade of follow-up,' Gabriel Bsteh, PhD, professor and neurologist at the Medical University of Vienna, and Harald Hegen, MD, PhD, researcher at Innsbruck Medical University, both in Austria, wrote in an accompanying editorial. Women had a higher mean annual relapse rate and were less likely to be prescribed teriflunomide, S1PR modulators, and anti-CD20s. The number of treated women decreased 18 months before childbirth, from 42.6% to 27.9% around the time of conception and 11.1% at childbirth. 'A Timely Wake-Up Call' A limitation of the study was that the data used were from an expert center on MS — the treatment disparity between sexes could be higher in nonexpert settings. Other limitations included a lack of data on potential pregnancy complications related to discontinuing DMT use and feasibility of replicating results in more diverse populations. 'Anticipation of pregnancy was probably an important factor in this difference between women and men with MS, but there could also be a reluctance to use these treatments when they may actually be the best way to manage the disease and delay disability,' Vukusic noted. Both Bsteh and Hegen called for clinicians to familiarize themselves with the latest guidelines for safe DMT use in pregnancy and increase education for patients. They described the findings as a 'timely wake-up call: Even as our therapeutic arsenal expands, sex-based inertia threatens to blunt its benefit for women with MS.'

Press Release: Sanofi completes the acquisition of Vigil Neuroscience, Inc.
Press Release: Sanofi completes the acquisition of Vigil Neuroscience, Inc.

Yahoo

time14 hours ago

  • Yahoo

Press Release: Sanofi completes the acquisition of Vigil Neuroscience, Inc.

Sanofi completes the acquisition of Vigil Neuroscience, Inc. Paris, August 6, 2025. Sanofi announces the completion of its acquisition of Vigil Neuroscience, Inc. ('Vigil'). This acquisition strengthens Sanofi's early-stage pipeline in neurology with VG-3927, a novel, oral, small-molecule TREM2 agonist, which will be evaluated in a phase 2 clinical study in patients with Alzheimer's disease. In addition, the acquisition of Vigil's preclinical pipeline will further strengthen Sanofi's research in various neurodegenerative diseases. In June 2024, Sanofi made a $40 million strategic investment in Vigil that included the exclusive right of first negotiation for an exclusive license, grant, or transfer of rights to research, develop, manufacture, and commercialize VG-3927. Under the terms of the acquisition agreement, Sanofi and Vigil have agreed to the following: Sanofi acquired all outstanding common shares of Vigil for $8 per share in cash at closing, representing an equity value of approximately $470 million (on a fully diluted basis) In addition, Vigil's shareholders received a non-transferrable contingent value right (CVR) per Vigil share, which entitles its holder to receive a deferred cash payment of $2, conditioned upon the first commercial sale of VG-3927. VGL101, Vigil's second clinical program, was not acquired by Sanofi. As previously communicated, the acquisition of Vigil is not expected to impact Sanofi's financial guidance for 2025. About Sanofi Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people's lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our is listed on EURONEXT: SAN and NASDAQ: SNY Media RelationsSandrine Guendoul | +33 6 25 09 14 25 | Berland | +1 215 432 0234 | Le Bourhis | +33 6 75 06 43 81 | Rouault | +33 6 70 93 71 40 | Gilbert | +1 516 521 2929 | Ubaldi | +33 6 30 19 66 46 | Investor RelationsThomas Kudsk Larsen | +44 7545 513 693 | Kaisserian | +33 6 47 04 12 11 | Lauscher | +1 908 612 7239 | Browne | +1 781 249 1766 | Pham | +33 7 85 93 30 17 | Elgoutni | +1 617 710 3587 | Châtelet | +33 6 80 80 89 90 | Li | +33 6 84 00 90 72 | Sanofi forward-looking statementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words 'expects', 'anticipates', 'believes', 'intends', 'estimates', 'plans' and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi's ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under 'Risk Factors' and 'Cautionary Statement Regarding Forward-Looking Statements' in Sanofi's annual report on Form 20-F for the year ended December 31, 2024. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. All trademarks mentioned in this press release are the property of the Sanofi Press ReleaseError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store